

Modified Form PTO-1449

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.

A-579B

Serial No.

09/890,729

Applicant

Yoshinaga, et al

Filing Date

January 27, 2000

Group

1644

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-	TRANSLATION

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

C1	Attwood, T., "The Babel of Bioinformatics", <i>Science</i> , 290: 471-473, (20 Oct 2000).
C2	Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> , 247: 1306-1310, (16 March 1990).
C3	Dai, Z. et al., "The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection", <i>Current Opinion in Immunology 1999 United Kingdom</i> , Vol. 11, No. 5, 504-508, (1999).
C4	Database EMBL [Online] "Homo sapiens mRNA for KIAA0653 protein, partial cds." EBI Accession No. AB014553, 15 July 1998.
C5	Database EMBL [Online] "yg34c12.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:34465 5', mRNA sequence." EBI Assession No. R23544, 23 April 1995.
C6	Database UNIPROT [Online] Wang, et al.: "ICOS ligand precursor (B7 homolog 2) (B7-H2) (B7-like protein G150) (B7-related protein 1) (B7RP-1) (CD275 antigen)", UNIPROT Assession No. 075144, 15 July 1999.
C7	Database UNIPROT [Online] O'Regan, et al., "ICOS ligand.", UNIPROT Assession No. 042404, 1 January 1998.
C8	Database EMBL [Online] "vg32f09.r1 Soares mouse mammary glad NbMMG Mus musculus cDNA clone IMAGE:863081 5', mRNA sequence.", EMBL Assession No. AA510455, 9 July 1997.
C9	Fick, R. B., et al., "Immunotherapy approach to allergic disease", <i>Immunopharmacology</i> , 48: 307-310, (25 July 2000).
C10	Heaney, Liam G., et al., "Severe asthma treatment: need for characterising patients", <i>Lancet</i> , 365: 974-976, (12 March 2005).

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No.	A-579B	Serial No.	09/890,729
	Applicant			
	Yoshinaga, et al			
	Filing Date	January 27, 2000	Group	1644

### OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

C11	Huang, Ziwei, "Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis", <i>Pharmacology &amp; Therapeutics</i> , 86: 201-215, (2000).
C12	Ishikawa, et al., "Prediction of the coding Sequences of Unidentified Human Genes. X. The Complete Sequences of 100 New cDNA Clones from Brain Which Can Code for Large Proteins <i>in vitro</i> ", <i>DNA Res.</i> , 5: 169-176 (1998)
C13	Kahan, Barry D., "Immunosuppressive therapy", <i>Current Opinion in Immunology</i> , 4: 553-559, (1992).
C14	Metzler, et al., "Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28", <i>Nature Structural Biology</i> , 4, No. 7: 527-531, (July 1997).
C15	The Merck Manual of Diagnosis and Therapy, Section 6 – Pulmonary Disorders, Chapter 68, Seventeenth Edition, Published by Merck Research Laboratories, Division of Merck & Co., Inc., Whitehouse Station, NJ, 556-557, (1999).
C16	Schultze, J., et al., "B7-mediated costimulation and the immune response", <i>Blood Reviews 1996 United Kingdom</i> , 10, No. 2, 111-127, (1996).
C17	Skolnick, Jeffrey, et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", <i>Trends in Biotechnology</i> , 18(1): 34-39, (January 2000).

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	